ICICI Direct has given Buy recommendation for Ajanta Pharmaceuticals with a target price of Rs. 1955 in its research report issued on May 11, 2022

ICICI Direct’s research report on Ajanta Pharmaceuticals

Ajanta Pharma is a focused player in branded, which constitutes ~72% of overall sales, spread across geographies including India. As of FY22, overall exports: domestic formulations ratio was at 70:30 • Among exports, Asia accounts for ~35% of export formulations, Africa 34% & US 30%. The company also participates in anti-malarial tenders in Africa (included in Africa).

Outlook

We maintain BUY as it remains a compelling play on branded generics (~72% exposure) with strong execution track record and financials. Valued at Rs 1955 i.e. 20x P/E on FY24E EPS of Rs 97.8.

Leave a Reply

Your email address will not be published.